From the rapid growth of wearable biosensors to the quiet revolution of lab automation, the medical diagnostics industry is undergoing a staggering expansion, with markets from liquid biopsy to point-of-care testing projected to add hundreds of billions in value this decade.
Key Takeaways
- The global in vitro diagnostics (IVD) market was valued at USD 85.2 billion in 2022 and is expected to grow at a CAGR of 3.9% from 2023 to 2030.
- The medical imaging market size was estimated at USD 42.67 billion in 2023 and is projected to reach USD 59.45 billion by 2030, exhibiting a CAGR of 4.8% from 2024 to 2030.
- The global point-of-care diagnostics market size was valued at USD 44.7 billion in 2023 and is anticipated to expand at a CAGR of 10.4% from 2024 to 2030.
- In vitro diagnostics accounted for 54% of the total diagnostics market revenue in 2023.
- Imaging diagnostics represented 28% of the global medical diagnostics market in 2022.
- Point-of-care (POC) testing held 22% share in the IVD market in 2023.
- Roche Diagnostics held 14.5% market share in the global IVD market in 2022.
- Abbott Laboratories commanded 12.8% share of the diagnostics market in 2023.
- Siemens Healthineers occupied 11.2% of the medical imaging market in 2023.
- North America accounted for 42% of the global diagnostics market revenue in 2023.
- Europe held 28% share in the IVD market in 2022.
- Asia Pacific represented 20% of the medical imaging market in 2023.
- AI integration in diagnostics expected to drive 25% market growth by 2030.
- Next-generation sequencing (NGS) adoption in diagnostics rose 18% YoY in 2023.
- Point-of-care ultrasound devices saw 22% increase in usage post-COVID.
The global medical diagnostics market is growing rapidly across many technologies and regions.
Key Companies & Shares
- Roche Diagnostics held 14.5% market share in the global IVD market in 2022.
- Abbott Laboratories commanded 12.8% share of the diagnostics market in 2023.
- Siemens Healthineers occupied 11.2% of the medical imaging market in 2023.
- Thermo Fisher Scientific had 10.5% share in molecular diagnostics in 2022.
- Danaher Corporation (Beckman Coulter) held 9.8% in IVD reagents market.
- Bio-Rad Laboratories captured 8.7% of immunoassay systems market in 2023.
- GE Healthcare led with 15.3% in MRI imaging segment in 2023.
- Philips Healthcare had 13.2% share in ultrasound diagnostics in 2022.
- Qiagen held 7.9% in companion diagnostics market in 2023.
- Hologic Inc. commanded 6.5% in tissue diagnostics in 2023.
- Becton Dickinson (BD) had 11.1% share in POC diagnostics.
- Illumina Inc. occupied 14.2% of NGS-based molecular diagnostics.
- Canon Medical Systems held 9.4% in CT scanners market.
- Ortho Clinical Diagnostics (QuidelOrtho) had 8.3% in immunoassay.
- Guardant Health led liquid biopsy with 12.6% share in 2023.
- BioMerieux SA held 7.2% in infectious disease diagnostics.
- Sysmex Corporation commanded 10.8% in hematology analyzers.
- Fujifilm Holdings had 6.9% in digital pathology.
- Medtronic plc occupied 9.1% in cardiac diagnostics devices.
- Arkray Inc. held 5.4% in diabetes diagnostics monitors.
Key Companies & Shares Interpretation
While the medical diagnostics industry boasts a constellation of specialized leaders—from Roche’s command of general IVD to Guardant’s lead in liquid biopsy—no single giant dominates the entire galaxy, proving the field is a competitive chessboard of precision rather than a monopoly.
Market Size & Growth
- The global in vitro diagnostics (IVD) market was valued at USD 85.2 billion in 2022 and is expected to grow at a CAGR of 3.9% from 2023 to 2030.
- The medical imaging market size was estimated at USD 42.67 billion in 2023 and is projected to reach USD 59.45 billion by 2030, exhibiting a CAGR of 4.8% from 2024 to 2030.
- The global point-of-care diagnostics market size was valued at USD 44.7 billion in 2023 and is anticipated to expand at a CAGR of 10.4% from 2024 to 2030.
- The U.S. diagnostics market size was valued at USD 107.2 billion in 2022 and is expected to grow at a CAGR of 5.6% from 2023 to 2030.
- The global molecular diagnostics market size was valued at USD 15.13 billion in 2022 and is projected to grow at a CAGR of 9.8% from 2023 to 2030.
- The worldwide diagnostics market is forecasted to reach USD 125 billion by 2028, growing at a CAGR of 6.2% from 2023.
- The companion diagnostics market size was valued at USD 7.9 billion in 2023 and is expected to grow at a CAGR of 12.5% from 2024 to 2030.
- The global lab automation market in diagnostics was valued at USD 5.2 billion in 2022 and is projected to reach USD 7.8 billion by 2030 at a CAGR of 5.2%.
- The digital pathology market size was estimated at USD 1.03 billion in 2023 and is poised to grow at a CAGR of 13.6% from 2024 to 2030.
- The global wearable diagnostics market was valued at USD 22.2 billion in 2022 and expected to grow at CAGR 20.3% to USD 145.8 billion by 2032.
- The IVD market in Europe was valued at EUR 22.5 billion in 2022, with a projected CAGR of 4.1% through 2028.
- The Asia Pacific diagnostics market is expected to grow at the highest CAGR of 7.8% from 2023 to 2030.
- The global self-testing and point-of-care diagnostics market reached USD 11.5 billion in 2023.
- The histopathology market size was USD 11.2 billion in 2022, growing at CAGR 7.5% to 2030.
- The clinical chemistry analyzers market was valued at USD 12.2 billion in 2023, with CAGR 6.8% forecast.
- The immunoassay market size stood at USD 29.4 billion in 2022 and is set to grow at 7.2% CAGR.
- The tissue diagnostics market was valued at USD 5.7 billion in 2023, projecting CAGR 7.1% to 2030.
- The global POCT market for infectious diseases was USD 4.8 billion in 2022, CAGR 8.5% expected.
- The liquid biopsy market size was USD 5.6 billion in 2023, growing at 16.1% CAGR.
- The remote diagnostics market is projected to reach USD 75.6 billion by 2027 at CAGR 15.2%.
- The U.S. molecular diagnostics market was USD 6.8 billion in 2022, CAGR 10.2% to 2030.
- Global diagnostics market revenue reached USD 95.5 billion in 2023.
- The cytogenetic testing market size was USD 1.4 billion in 2023, CAGR 9.8% forecast.
- The hemostasis diagnostics market valued at USD 4.2 billion in 2022, growing 6.4% CAGR.
- The infectious disease diagnostics market was USD 32.7 billion in 2023.
- The cancer diagnostics market size estimated USD 22.1 billion in 2023, CAGR 7.5%.
- The diabetes diagnostics market was USD 24.5 billion in 2022, projecting 5.9% CAGR.
- The cardiac diagnostics market valued at USD 15.3 billion in 2023.
- The neurology diagnostics market size USD 11.8 billion in 2022, CAGR 7.2%.
- The veterinary diagnostics market was USD 3.4 billion in 2023, growing 8.9% CAGR.
Market Size & Growth Interpretation
While the hefty core diagnostics market chugs along like a reliable freight train, the explosive growth in areas like liquid biopsies, wearable sensors, and digital pathology shows the industry is frantically laying high-speed rail to a future where your health is constantly monitored, precisely targeted, and diagnosed from a drop of blood or a data stream.
Regional Markets
- North America accounted for 42% of the global diagnostics market revenue in 2023.
- Europe held 28% share in the IVD market in 2022.
- Asia Pacific represented 20% of the medical imaging market in 2023.
- U.S. dominated with 38.5% of North American molecular diagnostics market.
- China’s diagnostics market grew at 9.2% CAGR from 2018-2023.
- Japan held 15% of Asia Pacific POC diagnostics market in 2023.
- Germany accounted for 22% of European imaging market.
- India’s IVD market was valued at USD 1.2 billion in 2023, CAGR 12.5%.
- Latin America diagnostics market share was 5% globally in 2023.
- Middle East & Africa expected to grow at 7.1% CAGR in IVD.
- U.K. held 12% of European molecular diagnostics market.
- Brazil’s diagnostics market reached USD 2.8 billion in 2022.
- South Korea’s imaging market grew 6.8% annually.
- Canada accounted for 25% of North American POC market.
- Australia’s diagnostics market valued at AUD 3.5 billion in 2023.
- France held 18% share in European tissue diagnostics.
- Mexico’s IVD market CAGR projected at 8.4% to 2030.
- Russia diagnostics market was USD 4.1 billion in 2022.
- Saudi Arabia expected highest CAGR 9.5% in MENA diagnostics.
- North America liquid biopsy market share 48% in 2023.
- Europe companion diagnostics 35% global share.
- Asia Pacific digital pathology fastest growing at 15.2% CAGR.
Regional Markets Interpretation
While North America remains the diagnosis powerhouse, the real pulse of the industry is quickening in the growth corridors of Asia and beyond, where booming demand is rapidly redrawing the global healthcare map.
Segment Breakdown
- In vitro diagnostics accounted for 54% of the total diagnostics market revenue in 2023.
- Imaging diagnostics represented 28% of the global medical diagnostics market in 2022.
- Point-of-care (POC) testing held 22% share in the IVD market in 2023.
- Molecular diagnostics comprised 15% of the total diagnostics market in 2023.
- Clinical chemistry analyzers accounted for 35% of the IVD reagents market in 2022.
- Immunoassays dominated with 42% share in the molecular diagnostics market in 2023.
- MRI systems held 25% of the medical imaging market by modality in 2023.
- Ultrasound imaging accounted for 31% of the imaging diagnostics segment in 2022.
- Infectious disease testing represented 38% of the IVD market applications in 2023.
- Oncology diagnostics made up 22% of the companion diagnostics market in 2023.
- Glucose monitoring devices held 45% share in diabetes diagnostics in 2022.
- Coagulation testing accounted for 28% of hemostasis diagnostics in 2023.
- Digital pathology software segment was 55% of the total digital pathology market in 2023.
- PCR-based tests comprised 60% of molecular diagnostics for infectious diseases in 2022.
- Blood tests held 65% dominance in routine diagnostics in 2023.
- CT scanners represented 22% of imaging equipment sales in 2023.
- Tissue diagnostics immunohistochemistry segment was 40% in 2023.
- Liquid biopsy ctDNA analysis accounted for 35% of the market in 2023.
- Home-use POC devices held 18% of the POC diagnostics market in 2022.
- Hematology analyzers made up 25% of lab automation in diagnostics.
- Cardiac biomarker tests were 30% of immunoassay applications in 2023.
- Neurological imaging with MRI held 40% in neurology diagnostics.
- Oncology segment accounted for 45% of companion diagnostics revenue.
- Infectious disease POC tests were 50% of POC market in emerging regions.
Segment Breakdown Interpretation
While the staggering market figures reveal that modern medicine is increasingly an intricate puzzle of test tubes and imaging screens, the sobering reality is that our health is now a landscape meticulously charted by percentages, where over half of all diagnostic clarity comes from a vial of blood, not a physician's intuition.
Trends & Innovations
- AI integration in diagnostics expected to drive 25% market growth by 2030.
- Next-generation sequencing (NGS) adoption in diagnostics rose 18% YoY in 2023.
- Point-of-care ultrasound devices saw 22% increase in usage post-COVID.
- CRISPR-based diagnostics technologies grew at 45% CAGR since 2020.
- Wearable biosensors for continuous glucose monitoring up 30% in sales 2023.
- Liquid biopsy tests for early cancer detection increased 28% in clinical trials.
- Digital pathology AI scanners improved diagnostic accuracy by 15%.
- Telepathology platforms usage surged 40% in rural areas 2023.
- Multiplex immunoassay panels adoption rose 25% for infectious diseases.
- Biosensor integration in IVD devices grew 19% market penetration.
- 3D imaging in diagnostics enhanced resolution by 35% in MRI tech.
- Home-based PCR testing kits sales up 55% since pandemic.
- Blockchain in diagnostics data security adopted by 12% of labs.
- Microfluidics in POC diagnostics reduced time by 70%.
- Photon-counting CT detectors improved image quality 50%.
- Single-cell sequencing in oncology diagnostics up 32%.
- Voice-activated diagnostic tools in use 18% more efficiently.
- Nanotechnology biosensors sensitivity increased 40x in tests.
- Hybrid PET/MRI systems installations rose 27% globally.
- mRNA-based diagnostics for vaccines developed 60% faster.
- AR/VR in surgical diagnostics training used by 35% programs.
- Quantum dots in imaging probes brightness up 100x.
- Edge computing in POC devices reduced latency 80%.
- Organ-on-a-chip diagnostics models accuracy 85% vs traditional.
- Federated learning in diagnostic AI preserved 99% data privacy.
- Exosome-based liquid biopsy sensitivity reached 95% for early detection.
Trends & Innovations Interpretation
It seems the diagnostic toolbox has thrown out its magnifying glass and upgraded to a high-speed, hyper-intelligent satellite array, where AI, CRISPR, and nanotechnology are conspiring not just to find illness, but to outsmart it before it even gets comfortable.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 3ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 4STATISTAstatista.comVisit source
- Reference 5FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 6PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 7IBISWORLDibisworld.comVisit source